Andrew Tsai
Stock Analyst at Jefferies
(0)
# 4590
Out of 5,235 analysts
20
Total ratings
40.00%
Success rate
-14.97%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Rocket Pharmaceutica... | Initiates Coverage On: Buy | 29 | 12.56 | 130.89% | 1 | Dec 18, 2024 | |
Marinus Pharma | Downgrades: Hold | 5 1 | 0.53 | -5.66% | 1 | Oct 25, 2024 | |
Sarepta Therapeutics | Initiates Coverage On: Buy | 165 | 124.56 | 32.47% | 1 | Oct 21, 2024 | |
Relmada Therapeutics | Upgrades: Buy | 4 13 | 0.48 | 2608.33% | 2 | Sep 17, 2024 | |
Rapport Therapeutics | Initiates Coverage On: Buy | 35 | 17.7 | 97.74% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 10 21 | n/a | n/a | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 33 | 4.52 | 630.09% | 1 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Buy | 1 15 | 3.12 | 380.77% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Hold | 3 | 0.92 | 226.09% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Hold | 32 3 | 0.6 | 400% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 23 16 | 17 | -5.88% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 20 | 1.91 | 947.12% | 1 | Feb 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 55 70 | 83.24 | -15.91% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 27 | 1.75 | 1442.86% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 18 | n/a | n/a | 1 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Buy | 16 23 | n/a | n/a | 1 | Jun 1, 2020 |